LENZ Therapeutics (LENZ) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChartTranscripts

LENZ Stock Forecast


LENZ Therapeutics (LENZ) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $51.00, with a high of $51.00 and a low of $51.00. This represents a 27.47% increase from the last price of $40.01.

$15 $23 $31 $39 $47 $55 High: $51 Avg: $51 Low: $51 Last Closed Price: $40.01

LENZ Stock Rating


LENZ Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

LENZ Price Target Upside V Benchmarks


TypeNameUpside
StockLENZ Therapeutics27.47%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends


1M3M12M
# Anlaysts--1
Avg Price Target--$51.00
Last Closing Price$40.01$40.01$40.01
Upside/Downside--27.47%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 2535---8
Aug, 2535---8
Jul, 2535---8
Jun, 2535---8
May, 2535---8
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2025Biren AminPiper Sandler$51.00$23.24119.45%27.47%
Aug 15, 2024Joseph CatanzaroPiper Sandler$36.00$22.2561.80%-10.02%
Aug 15, 2024Yigal NochomovitzCitigroup$32.00$23.5036.17%-20.02%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Jul 31, 2025CitigroupBuyBuyhold
Jul 28, 2025H.C. WainwrightBuyBuyhold
Sep 26, 2024Raymond JamesOutperforminitialise
Aug 15, 2024Piper SandlerOverweightOverweighthold
Aug 15, 2024CitigroupBuyBuyhold
Apr 15, 2024William BlairOutperforminitialise
Apr 09, 2024CitigroupBuyinitialise

Financial Forecast


EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-15.30-----
Avg Forecast$-12.25$-2.82$-2.38$-2.21$-0.33$1.46
High Forecast$-6.44$-2.60$-2.00$-1.16$-0.17$2.25
Low Forecast$-18.95$-2.95$-2.93$-3.41$-0.50$0.77
Surprise %24.90%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$8.19M$52.04M$125.68M$198.22M
High Forecast--$11.84M$73.92M$178.52M$281.56M
Low Forecast--$5.30M$33.05M$79.83M$125.90M
Surprise %------

Net Income Forecast

$-200M $-150M $-100M $-50M $0 $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-124.65M-----
Avg Forecast$-99.78M$-22.99M$-19.40M$-17.98M$-2.65M$11.87M
High Forecast$-52.46M$-21.20M$-16.27M$-9.45M$-1.39M$18.36M
Low Forecast$-154.32M$-24.05M$-23.83M$-27.81M$-4.09M$6.24M
Surprise %24.93%-----

LENZ Forecast FAQ


Is LENZ Therapeutics stock a buy?

LENZ Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that LENZ Therapeutics is a favorable investment for most analysts.

What is LENZ Therapeutics's price target?

LENZ Therapeutics's price target, set by 4 Wall Street analysts, averages $51 over the next 12 months. The price target range spans from $51 at the low end to $51 at the high end, suggesting a potential 27.47% change from the previous closing price of $40.01.

How does LENZ Therapeutics stock forecast compare to its benchmarks?

LENZ Therapeutics's stock forecast shows a 27.47% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and underperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for LENZ Therapeutics over the past three months?

  • September 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is LENZ Therapeutics’s EPS forecast?

LENZ Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.82, marking a -81.57% decrease from the reported $-15.3 in 2023. Estimates for the following years are $-2.38 in 2025, $-2.21 in 2026, $-0.33 in 2027, and $1.46 in 2028.

What is LENZ Therapeutics’s revenue forecast?

LENZ Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $8.19M, followed by $52.04M for 2026, $125.68M for 2027, and $198.22M for 2028.

What is LENZ Therapeutics’s net income forecast?

LENZ Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-22.994M, representing a -81.55% decrease from the reported $-125M in 2023. Projections indicate $-19.398M in 2025, $-17.984M in 2026, $-2.647M in 2027, and $11.87M in 2028.